What we do Bliss GVS Pharma Ltd manufactures, markets, and exports pharmaceutical products with WHO GMP-certified facilities, serving global markets including the US, Europe, and Africa. |
Founded in 1,984 |
Market share Strong presence in regulated and emerging markets through contract manufacturing and product innovation, growing revenue primarily from exports. |
Problem solved Provides high-quality, affordable pharmaceutical formulations addressing healthcare needs in multiple therapeutic areas worldwide. |
Top clients or who we serve Serves global B2B clients in regulated markets like US, Canada, Europe, and emerging markets in Africa; also B2C distribution through partners. |
Key management Mr. Gagan Harsh Sharma (Managing Director), Dr. Vibha Gagan Sharma (Whole-Time Director) with strong leadership and pharma expertise. |
Our journey and innovations Started in 1985, obtained USFDA approval in 2024, expanded manufacturing capacity, focused on R&D with DSIR-recognized center, and strategic global partnerships. |
Where we operate India, US, Canada, Europe, Africa (Kenya, Nigeria, Ghana), and other international markets. |
Top products or what we offer Tablets, capsules, dry syrups, sachets, semi-solid formulations from advanced USFDA and WHO GMP facilities. |
Top brands VAGID (noted product), alongside contract manufacturing services driving exports to regulated markets. |
Raw materials needed Pharmaceutical active ingredients and excipients sourced globally for formulation manufacturing. |
Raw materials supplier Details not specified; sourced from trusted global suppliers adhering to quality standards. |
Recurring vs cyclical contribution Majority of revenue is recurring, driven by consistent export orders and contract manufacturing agreements. |
Our industry position Recognized player with steady growth in regulated markets and strong compliance track record including USFDA approval. |
Financial highlights Revenue Rs. 809.73 crore with Net Profit Rs. 84.3 crore for FY 2025; consolidated revenue Rs. 846 crore, showing growth over previous year. |
Geographical revenue split About 90% revenue from outside India, primarily from regulated and emerging international markets. |
Order book - |
Whats driving growth New product launches, entry into regulated markets, USFDA approval, contract manufacturing, and enhanced global client partnerships. |
Our future plans Expand production capacity at Vevoor, invest in R&D, pursue more regulated market approvals, and enhance sustainability via solar energy. |
Our green promise Installed 2.5 MW solar capacity in 2025 to reduce carbon footprint and improve energy efficiency. |
Our people and values Focus on talent retention through ESOP, fostering inclusive culture and high performance with continuous training programs. |
Key challenges ahead Regulatory compliance in diverse markets, competition, supply chain risks, and timely product registrations. |
Interesting facts Successfully divested non-core subsidiaries to focus on pharmaceuticals; DSIR approved R&D center since 2014; strong ESG initiatives. |
Risks and strategy Mitigates regulatory and operational risks through quality controls, diversified markets, and continuous innovation. |
